Musso Alan A 4
4 · Fulcrum Therapeutics, Inc. · Filed Jan 19, 2024
Insider Transaction Report
Form 4
Musso Alan A
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2024-01-17+61,822→ 61,822 totalExercise: $4.01From: 2024-02-07Exp: 2033-08-06→ Common Stock (61,822 underlying)
Footnotes (1)
- [F1]This performance-based stock option was granted on August 7, 2023 and is subject to the achievement of certain pre-defined performance objectives pertaining to financial and investor relations goals within six months from the grant date, and subject to Mr. Musso continuing to be an "eligible participant" (as defined in Fulcrum Therapeutics, Inc.'s 2022 Inducement Stock Incentive Plan) through the vesting date. All performance objectives were met on January 17, 2024.